The Role of CD-19 Targeting Chimeric Antigen Receptor (CAR) T-cell Therapy in Non-Hodgkin Lymphoma

Chimeric Antigen Receptor (CAR) T-cell therapy has improved outcomes in multiple hematological malignancies, such as multiple myeloma and non-Hodgkin lymphoma. CD-19 targeting CAR T-cells have improved outcomes in both aggressive and indolent types of non-Hodgkin lymphoma. Four CAR T-cell products have been approved by the United States (U.S.) Food and Drug Administration (FDA) for the management of non-Hodgkin lymphoma. This article reviews the currently available commercial CAR T-cells products' role in managing diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We summarize pivotal clinical trials and real-world data on their efficacy and safety.